nach oben

American Journal of Clinical Dermatology

Erschienen in:

01.08.2007 | Leading Article

Cancer Concerns with Topical Immunomodulators in Atopic Dermatitis

Overview of Data and Recommendations to Clinicians

verfasst von: Tejesh S. Patel, Sarah C. Greer, Dr Robert B. Skinner Jr

Erschienen in: American Journal of Clinical Dermatology | Ausgabe 4/2007

Einloggen, um Zugang zu erhalten

Abstract

The topical immunomodulators tacrolimus and pimecrolimus were approved for the treatment of atopic dermatitis in 2000 and 2001, respectively. However, on 20 January 2006, the US FDA approved a ‘black box’ warning for these agents because of concerns regarding a possible link to development of malignancy. These concerns were based upon the known mechanism of action of this drug class, the results of animal studies, and case reports. This article provides an overview of the data that led to the approval by the FDA of a ‘black box’ warning and concludes that physicians, patients, and caregivers should feel confident about using tacrolimus and pimecrolimus for atopic dermatitis so long as they follow the FDA guidelines.

Berger TG, Duvic M, Van Voorhees AS, et al.The use of topical calcineurin inhibitors in dermatology: safety concerns]. Report of the American Academy of Dermatology Association Task Force. J Am Acad Dermatol 2006 May; 54 (5):818–23

Barneston RS, Rogers M.Childhood atopic eczema. BMJ 2002 Jun; 324 (7350): 1376–9CrossRef

Leung DY, Nicklas RA, Li JT, et al.Disease management of atopic dermatitis: an updated practice parameter. Joint Task Force on Practice Parameters. Ann Allergy Asthma Immunol 2004 Sep; 93 (3 Suppl. 2): 1–21

Akdis CA, Akdis M, Bieber T, et al.Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report.Allergy 2006 Aug; 61 (8): 969–87PubMedCrossRef

Hultsch T, Kapp A, Spergel J. Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis. Dermatology 2005; 211 (2): 174–87PubMedCrossRef

Leung DY, Boguniewicz M, Howell MD, et al.New insights into atopic dermatitis. J Clin Invest 2004; 113 (5): 651–7PubMed

Allam JP, Novak N. The pathophysiology of atopic eczema. Clin Exp Dermatol 2006 Jan; 31 (1): 89–93PubMedCrossRef

Novak N, Bieber T. The role of dendritic cell subtypes in the pathophysiology of atopic dermatitis. J Am Acad Dermatol 2005 Aug; 53(2 Suppl. 2): 171–6CrossRef

Ring J, Barker J, Behrendt H, et al. Review of the potential photo-cocarcinogenicity of topical calcineurin inhibitors: position statement of the European Dermatology Forum. J Eur Acad Dermatol Venereol 2005 Nov; 19 (6): 663–71PubMedCrossRef

10.

Sauder DN. Mechanism of action and emerging role of immune response modifier therapy in dermatologic conditions. J Cutan Med Surg 2004; 8 (3 Suppl.): 3–12PubMedCrossRef

11.

Norris DA. Mechanisms of action of topical therapies and the rationale for combination therapy. J Am Acad Dermatol 2005 Jul; 53 (1 Suppl. 1): 17–25CrossRef

12.

Wooltorton E. Eczema drugs tacrolimus (Protopic) and pimecrolimus (Elidel): cancer concerns. CMAJ 2005 Apr; 172 (9): 1179–80PubMedCrossRef

13.

Novartis Pharmaceuticals Corp. Elidel [package insert]. East Hanover (NJ): Novartis Pharmaceuticals Corp., 2006 Jan 19 [online].

14.

Astellas Pharma US Inc. Protopic [package inset]. Deerfield (IL): Astellas Pharma US Inc., 2006 [online]. Available from URL: http://www.fda.gov/cder/durg/infopage/protopic/MG_20060119.pdf [Accessed 2006 Aug 30]

15.

Panhans-Gross A, Novak N, Kraft S, et al. Human epidermal Langerhans’ cells are targets for the immunosuppressive macrolide tacrolimus (FK506). J Allergy Clin Immunol 2001; 107 (2): 345–52PubMedCrossRef

16.

Wollenberg A, Sharma S, von Bubnoff D, et al. Topical tacrolimus (FK506) leads to profound phenotypic and functional alterations of epidermal antigen-presenting dendritic cells in atopic dermatitis. J Allergy Clin Immunol 2001; 107 (3): 519–25PubMedCrossRef

17.

Hoetzenecker W, Meingassner JG, Ecker R, et al. Corticosteroids but not pimecrolimus affect viability, maturation and immune function of murine epidermal Langerhan cells. J Invest Dermatol 2004; 122 (3): 673–84PubMedCrossRef

18.

Novartis and Fujisawa FDA briefing statements: Pediatric Advisory Committee Meeting of the US Food Drug Administration, Washington, DC, 2005 [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4089b2.htm [Accessed 2006 Oct 1]

19.

Jonas S, Rayes N, Neumann U, et al. De novo malignancies after liver transplantation using tacrolimus-based protocols or cyclosporine-based quadruple immunosuppression with an interleukin-2 receptor antibody or antithymocyte globulin. Cancer 1997 Sep 15; 80 (6): 1141–50PubMedCrossRef

20.

Callen J, Chamlin S, Eichenfield LF, et al. A systemic review of the safety of topical therapies for atopic dermatitis. Br J Dermatol 2007; 156 (2): 203–21PubMedCrossRef

21.

Harper J, Smith C, Rubins A, et al. A multicenter study of the pharmacokinetics of tacrolimus ointment after first and repeated application to children with atopic dermatitis. J Invest Dermatol 2005 Apr; 124 (4): 695–9PubMedCrossRef

22.

Sotor NA, Fleischer AB Jr, Webster GF, et al. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II. Safety. J Am Acad Dermatol 2001 Jan; 44 (1 Suppl.): 39S–46SCrossRef

23.

Allen BR, Lakhanpaul M, Morris A, et al. Systemic exposure, tolerability, and efficacy of pimecrolimus cream 1% in atopic dermatitis patients. Arch Dis Child 2003 Nov; 88 (11): 969–73PubMedCrossRef

24.

Harper J, Green A, Scott G, et al. First experience of topical SDZ ASM 981 in children with atopic dermatitis. Br J Dermatol 2001 Apr; 144 (4): 781–7PubMedCrossRef

25.

Draelos Z, Nayak A, Pariser D, et al. Pharmacokinetics of topical calcineurin inhibitors in adult atopic dermatitis: a randomized, investigator-blind comparison. J Am Acad Dermatol 2005 Oct; 53 (4): 602–9PubMedCrossRef

26.

Ormerod AD. Topical tacrolimus and pimecrolimus and the risk of cancer: how much cause for concern? Br J Dermatol 2005 Oct; 153 (4): 701–5PubMedCrossRef

27.

Papp KA, Breuer K, Meurer M, et al. Long-term treatment of atopic dermatitis with pimecrolimus cream 1% in infants does not interfere with the development of protective antibodies after vaccination. Am Acad Dermatol 2005 Feb; 52 (2): 247–53CrossRef

28.

Stiehm E, Roberts R, Kaplan M, et al. Pneumococcal seroconversion after vaccination for children with atopic dermatitis treated with tacrolimus ointment. J Am Acad Dermatol 2005 Aug; 53 (2 Suppl. 2): 206–13CrossRef

29.

Wahn U, Bos JD, Goodfield M, et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 2002; 110: e2 [online]. Available from URL: http://www.pediatrics.org/cgi/content/full/110/1/e2 [Accessed 2006 Oct 7]CrossRef

30.

Reitamo S, Wollenberg A, Schopf E, et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis: the European Tacrolimus Ointment Study Group. Arch Dermatol 2000 Aug; 136 (8): 999–1006PubMedCrossRef

31.

Allen A, Siegfried E, Silverman R, et al. Significant absorption of topical tacrolimus in 3 patients with Netherton syndrome. Arch Dermatol 2001 Jun; 137 (6): 747–50PubMed

32.

Allen DM, Esterly NB. Significant systemic absorption of tacrolimus after topical application in a patient with lamellar ichthyosis. Arch Dermatol 2002 Sep; 138 (9): 1259–60PubMedCrossRef

33.

Oji V, Beljan G, Beier K, et al. Topical pimecrolimus: a novel therapeutic option for Netherton syndrome. Br J Dermatol 2005 May; 153 (5): 1067–8PubMedCrossRef

34.

Simon GA, Maibach HI. Relevance of hairless mouse as an experimental model of percutaneous penetration in man. Skin Pharmacol Appl Skin Physiol 1998 Mar-Apr; 11 (2): 80–6PubMedCrossRef

35.

Richardson K. Labeling changes for the topical calcineurin inhibitors: an expert interview with Mark Lebwohl, MD [online]. Available from URL: http://www.medscape.com/viewarticle/527614 [Accessed 2006 Oct 1]

36.

Jiang H, Yamamoto S, Nishikawa K, et al. Anti-tumor-promoting action of FK506, a potent immunosuppressive agent. Carcinogenesis 1993 Jan; 14 (1): 67–71PubMedCrossRef

37.

Niwa Y, Terashima T, Sumi H. Topical application of the immunosuppressant tacrolimus accelerates carcinogenesis in mouse skin. Br J Dermatol 2003 Nov; 149 (5): 960–7PubMedCrossRef

38.

Tran C, Lubbe J, Sorg O, et al. Topical calcineurin inhibitors decrease the production of UVB-induced thymine dimers from hairless mouse epidermis. Dermatology 2005; 211 (4): 341–7PubMedCrossRef

39.

James WD, Berger TG, Elston DM. Andrews’ diseases of the skin: clinical dermatology. 10th ed. Philadelphia (PA): Saunders Elsevier, 2006

40.

Temeck J. Protopic and Elidel presentation for regulatory briefing on January 14, 2005 [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4089b2_01_02_DPDD%20Consult.pdf [Accessed 2006 Sep 22]

41.

Stern RS. Topical calcineurin inhibitors labeling: putting the ‘box’ in perspective. Arch Dermatol 2006; 142: 1233–4PubMedCrossRef

Titel: Cancer Concerns with Topical Immunomodulators in Atopic Dermatitis
Overview of Data and Recommendations to Clinicians
verfasst von: Tejesh S. Patel
Sarah C. Greer
Dr Robert B. Skinner Jr
Publikationsdatum: 01.08.2007
Verlag: Springer International Publishing
Erschienen in: American Journal of Clinical Dermatology / Ausgabe 4/2007
Print ISSN: 1175-0561
Elektronische ISSN: 1179-1888
DOI: https://doi.org/10.2165/00128071-200708040-00001

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

Studienlage spricht für Isotretinoin zur Rosazea-Therapie

23.05.2024 Rosazea Nachrichten

Isotretinoin wird off-label zur Behandlung von Rosazea eingesetzt. Wie solide die Evidenz dafür ist, wurde jetzt in einem systematischen Review überprüft.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Riesenzellarteriitis: 15% der Patienten sind von okkulter Form betroffen

16.05.2024 Riesenzellarteriitis Nachrichten

In einer retrospektiven Untersuchung haben Forschende aus Belgien und den Niederlanden die okkulte Form der Riesenzellarteriitis genauer unter die Lupe genommen. In puncto Therapie und Rezidivraten stellten sie keinen sehr großen Unterschied zu Erkrankten mit kranialen Symptomen fest.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Bildnachweise

Die Leitlinien für Ärztinnen und Ärzte, Nahaufnahme Rosazea auf der Wange/© Alessandro Grandini / stock.adobe.com (Symbolbild mit Fotomodell), Eine Tätowierung wird mit roter Farbe ausgefüllt/© nagaets / stock.adobe.com (Symbolbild mit Fotomodell), Operation/© Peakstock / Stock.adobe.com (Symbolbild mit Fotomodellen), Rechte Aa. carotis interna mit Wandverdickung bei Riesenzellarteriitis/© Kisyova H et al. | all rights reserved Springer Medizin Verlag GmbH

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2007

Aggressive Digital Papillary Adenocarcinoma

Persistent Non-Tender Swelling of the Upper Lip

Merkel Cell Carcinoma in a Liver Transplant Patient

Efficacy of Oral Fluconazole in the Treatment of Seborrheic Dermatitis

Book Reviews